SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to high volatility and a potential short squeeze, fueled by its low float and lack of active shelf offerings. The community is actively discussing price targets and the possibility of a significant run, drawing comparisons to other stocks with similar setups. The stock has experienced multiple trading halts, contributing to the intense interest and speculation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Shares of Netflix are under pressure, as the community debates the potential outcomes of the Warner Bros. Discovery bidding war. Some believe Netflix is overpaying or taking on too much debt with the deal, while others speculate about potential regulatory hurdles, a breakup fee, or the company's prospects if the deal falls through. Overall, the stock's recent performance has spurred a lot of discussion about its current valuation and future direction.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its low float, high volatility, and unique position as a hybrid infrastructure play in the crypto mining sector. Community members are anticipating updates from the company's upcoming conference, which could act as a major catalyst. Traders are drawn to MIGI's explosive potential, as even small buys can significantly move the price.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the market anticipates the Fed's rate decision and Powell's press conference, with community members debating the potential impact on the market's direction. Discussions revolve around whether the Fed will cut rates, the possibility of QE, and the implications of a hawkish or dovish stance. Some traders are also noting news of the U.S. seizing an oil tanker off Venezuela, adding another layer of uncertainty.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending as community members discuss its failure to keep pace with broader market gains and its underperformance relative to other tech giants. Some speculate on potential shifts in AI partnerships and the impact of competition from Google, while others point to institutional accumulation and long-term growth potential. The stock's struggle to surpass key resistance levels is also a focal point of discussion.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as the market anticipates potential rate cuts, especially after recent dovish signals from Fed officials. Community discussions revolve around whether current valuations justify further upside, with some expressing concerns about a potential AI bubble. Bond market participants are closely watching economic data releases for further cues on the Fed's policy path.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending as discussions revolve around the potential impact of SpaceX's increased valuation and possible IPO on the space sector, with community members drawing valuation comparisons. Anticipation is building for the company's upcoming launch, while some traders discuss technical indicators and potential short squeezes.

Oriental Culture Holding Ltd. operates as a holding company, which is engaged in providing collectibles and artwork e-commerce services through its subsidiaries. The firm facilitates trading by individual customers of all kinds of collectibles, artwork, and certain commodities on its online platform owned by its subsidiary in Hong Kong, namely the China International Assets and Equity of Artworks Exchange Limited. It provides services including investor education, market information, customer support, and technology infrastructure. The company was founded in March 2018 and is headquartered in Hong Kong.

Oriental Culture Holding Ltd

OCG is experiencing significant volatility, with community discussions focused on a large price swing and whether it's a pump and dump. Some traders are taking profits and moving to other tickers like $LDWY and $MIGI, while others are hoping for a continued run. The stock's movements are being compared to other recent low-float runners, particularly within the Hong Kong stock sector.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to a recent patent allowance for its EVM301 series, sparking discussion of a potential short squeeze given the stock's low float. The community is weighing the significance of the new IP against the company's history of dilution, while also speculating about a possible settlement with AbbVie. Some traders express optimism for a continued run, while others remain cautious.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending downwards, with community discussion focusing on potential competition from Waymo and the stock's recent performance despite positive fundamentals. Some investors are speculating about a buying opportunity, while others express concern about the stock's price action and potential manipulation. The recent partnership announcements and broader trends in the autonomous vehicle space are also being closely watched.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IO Biotech (NASDAQ:IOBT) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen raised IO Biotech from a "sell" rating to a "hold" rating in a research report on Sunday...

IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why

IO Biotech, Inc. (IOBT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology PR Newswire NEW...

IO Biotech (IOBT) stock slumped 77% by Monday afternoon after the company announced that the U.S. Food and Drug Administration (FDA) recommended that the firm conduct another trial before submitting Cylembio for approval.IO Biotech held a meeting with the agency, which recommended that the firm not submit an application based on data from the IOB-013 clinical trial, in which Cylembio plus Merck’s Pembrolizumab improved progression-free survival (PFS), but narrowly missed statistical significance.“We look forward to continuing the dialogue with FDA to align on the design for a potential new registrational study. Additionally, we plan to discuss the data from our IOB-013 study with European regulators and determine a path to submission in the EU,” CEO Mai-Britt Zocca <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.iobiotech.com/news-events/news/news-details/2025/IO-Biotech-Provides-Update-Following-Pre-BLA-Meeting-with-FDA/default.aspx">said</a>.The company also stated that it is implementing a plan to conserve capital while seeking approval for the drug and conducting ongoing studies. IO Biotech currently has capital to sustain its operation into the first quarter of 2026. However, it is now planning restructuring, including a halving of its workforce.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_2_10_50_PM_png_0d2cc62fff.webp" alt="IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>IOBT's Sentiment Meter and Message Volume as of 2:11 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target, as per TheFly. Given its cash position, the company would either need to raise additional capital, partner, or license out Cylembio to advance the new trial, the analyst noted.IO Biotech had <a href="https://stocktwits.com/news-articles/markets/equity/io-biotech-trial-of-cancer-therapy-plus-keytruda-misses-study-goal/chrHGKVRdeB">announced</a> in August that the late-stage trial of its investigational and therapeutic cancer vaccine, Cylembio, in combination with Pembrolizumab, failed to achieve statistical significance in terms of progression-free survival improvement compared to Keytruda alone.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved a median progression-free survival of 19.4 months, compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the duration of time during and after cancer treatment during which a patient lives without the disease worsening.IOBT stock is down 61% this year and approximately 66% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/enanta-pharmaceuticals-stock-rises-despite-rsv-treatment-mid-stage-trial-failing-main-goal/chDuJaER3JS">Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

IO Biotech Stock Plunges After FDA Recommends Another Trial For Investigational Cancer Vaccine

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 

Equity

Following the announcement, H.C. Wainwright downgraded IO Biotech to ‘Neutral’ from ‘Buy’ with no price target. 


IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know

IO Biotech, Inc. (IOBT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with Merck’s (MRK) Keytruda, failed to achieve statistical significance in progression-free survival improvement in a late-stage trial compared to Keytruda alone.IOBT stock traded over 19% lower on Monday morning, at the time of writing. The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://iobiotech.com/press-releases/?workflow=6562e614-30a0-4300-9a37-ab75253933a2">said</a> Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed. Improvement in progression-free survival was achieved across virtually all subgroups, including those with poor prognostic factors, the company said.The trial evaluated Cylembio in combination with Keytruda versus Keytruda alone in 407 patients with previously untreated, unresectable, or metastatic (advanced) melanoma. Patients in the study treated with Cylembio in combination with Keytruda achieved 19.4 months of median progression-free survival compared to 11.0 months in patients treated with Keytruda alone. Progression-free survival (PFS) refers to the length of time during and after cancer treatment that a patient lives without the disease worsening.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IOBT">IOBT</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:625/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_11_at_9_43_00_AM_png_243b1797b9.webp" alt="IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits" width="625" height="61"><figcaption>IOBT's Sentiment Meter and Message Volume as of 9:43 a.m. ET on Aug. 11, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the data.<stembedurl>https://stocktwits.com/Notnotshort/message/624573071</stembedurl>Another opined that the stock price should multiply by 10 times in the aftermath of the data release.<stembedurl>https://stocktwits.com/Abo_Hamza/message/624572510</stembedurl>A trend toward an improvement in overall survival was also observed in the study, though data is not yet mature, the company said. Overall survival (OS) is a key metric in clinical trials, particularly for cancer, representing the length of time from a specific event (like diagnosis or treatment start) that patients remain alive.“The magnitude and durability of clinical effect observed consistently across subgroups supports our confidence in Cylembio and its potential as a treatment for advanced melanoma patients. We look forward to engaging with the FDA to determine a potential path to approval based on these data,” said Mai-Britt Zocca, CEO of IO Biotech.IO Biotech plans to meet with the U.S. Food and Drug Administration (FDA) this fall to discuss the data and determine next steps for submission of a Biologics License Application (BLA) for the treatment of advanced melanoma.IOBT stock is up by 59% this year and by about 12% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/kroger-reaches-settlement-with-c-and-s-wholesale-grocers/chruzkSRdec">Big News On Kroger! Company Reaches Settlement With C&amp;S Wholesale Grocers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed.

IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN Research Report) and IO Biotech...

IO Biotech's Promising Phase 3 Cancer Vaccine Trial Advances

The latest announcement is out from IO Biotech (IOBT). On August 30, 2024, the Company revealed positive news from its Phase 3 trial of the cancer...

IO Biotech appoints Faical Miyara as CBO

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

IOBT
IO Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOBT News

IOBTIO Biotech Inc